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INTRODUCTION
Drug reaction with eosinophilia and systemic symptoms 
(DRESS) is a rare, potentially life-threatening, drug-induced hy-
persensitivity reaction that includes skin eruption, hematologic 
abnormalities (eosinophilia, atypical lymphocytosis), lymph-
adenopathy, and internal organ involvement.1-3 DRESS initially 
was observed in patients treated with anticonvulsants in the ear-
ly 1930s, when phenytoin first became available.4 Many clinical 
terms have been used to describe DRESS, including hypersen-
sitivity syndrome and mononucleosis-like syndrome.2 In 1996, 
Bocquet et al.1 proposed the term DRESS “to decrease the ambi-
guity of the denomination of hypersensitivity syndrome” and to 
give a more accurate description of this clinical syndrome. The 
incidence of DRESS ranges from 1 in 1000 to 1 in 10,000 drug 
exposures.5Aromatic anticonvulsants (especially phenytoin, car-
bamazepine, and phenobarbital) and sulfonamides (such as dap-
sone and sulfasalazine) are the most common causes of DRESS.1,6
This case report and review revisits the association be-
tween sulfasalazine and DRESS and reminds clinicians to 
consider this entity as part of a broad differential diagno-
sis when evaluating patients who experience unusual clini-
cal manifestations after starting this culprit medication.
CASE REPORT
A 46-year-old African American female with Crohn’s disease, 
complicated by enterocutaneous fistulas and status-post small 
bowel resection, acid reflux, and chronic migraines presented 
in early 2016 for new onset rash involving her face, arms, ab-
domen, and upper thighs. She had seen her rheumatologist 
1.5 weeks prior to admission, at which time she was started 
on sulfasalazine. Her primary care physician around the same 
time had started her on ranitidine for acid reflux.  Both agents 
were stopped prior to admission, but the rash persisted. She 
also was taking amitriptyline, cetirizine, citalopram, cyclo-
benzaprine, diclofenac gel, diphenhydramine, ergocalciferol, 
fluticasone, lidocaine patch, morphine SR, ondansetron, and 
oxycodone as needed. She was not on steroids prior to arrival.
On admission, she was febrile, tachycardic, tachypneic, 
and appeared ill. She had an erythematous, pruritic, macu-
lopapular rash involving her face, arms, abdomen, and up-
per thighs without drainage. No abscesses were noted. Her 
labs revealed a sodium level of 125 mmol/L (low), a total bili-
rubin of 2.5 mg/dL (high), an alkaline phosphatase of 136 U/L 
(high), a lactate of 2.7 mmol/L (high), white blood cell count 
of 5,800/mcL, platelet count of 123,000/mcL, hemoglobin of 
11.8 gm/dL (low), and 18% “other cells”. Peripheral smear re-
vealed reactive and atypical lymphocytes with mild monocy-
tosis. LDH was elevated at 500 U/L, haptoglobin was low at < 
30 mg/dL, and reticulocyte count was elevated; all consistent 
with acute hemolysis. The acute hepatitis panel was negative.
She initially was started on broad-spectrum antibiotics for 
suspected severe sepsis of undetermined etiology in the set-
ting of chronic immunosuppression from Crohn’s disease.  The 
other differentials on admission were drug reaction versus 
DRESS. Dermatology initially was unconvinced about the di-
agnosis of DRESS since the patient’s rash did not fit the typi-
cal chronological pattern consistent with DRESS. It had been 
only 1.5 weeks since she had begun the suspected medications.
Hematology was consulted due to the patient’s hemolytic 
anemia. A Coomb’s test, plasma free hemoglobin, and G6PD 
test were within normal limits. Flow cytometry revealed reac-
tive T cell lymphocytosis. The patient had an abdominal ultra-
sound which showed a peripheral splenic infarct. Infectious 
disease tested for an Epstein-Barr virus (EBV), cytomegalovirus, 
human herpesvirus 6, parvovirus B19, and adenovirus PCRs, 
HIV antigen/antibody, and syphilis and Cryptococcus antigens. 
Only the EBV panel was positive. Other pertinent negative tests 
included ceruloplasmin, anti-neutrophil cytoplasmic antibod-
ies, anti-Saccharomyces cerevisiae antibodies, antimitochon-
drial antibody, antinuclear antibody, and alkaline phosphatase.
The patient developed severe facial edema within a few days 
of admission. Otolaryngology performed a flex exam revealing 
no oropharyngeal or supraglottic swelling and a patent airway. 
Biopsy performed by dermatology was most consistent with 
DRESS and showed no evidence of Stevens Johnson syndrome 
or toxic epidermal necrolysis. Dermatology suspected the culprit 
drug was sulfasalazine over ranitidine. Antibiotics were discon-
tinued at that time and high-dose systemic corticosteroid therapy 
was initiated (prednisone 80 mg daily). She also was started on 
a proton pump inhibitor, calcium, vitamin D supplementation, 
and dapsone for prophylaxis for Pneumocystis jiroveci pneumo-
nia (PJP) while on a prolonged systemic corticosteroid course.
Aerosolized pentamidine and atovaquone were dis-
cussed with the patient but dapsone was considered best 
option due to cost. Dapsone can cause DRESS, but the 
patient was initiated on high-dose systemic corticoste-
roid therapy and the risk for PJP was deemed very high. 
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There was a risk-benefit discussion with the patient and she elect-
ed to take dapsone therapy. The patient’s symptoms markedly 
improved and she had appropriate follow-up. The patient did 
well on dapsone therapy and did not develop any complications.
DISCUSSION
This patient’s symptoms and clinical findings were difficult 
to interpret on admission. First, the onset of symptoms with 
DRESS typically occurs two to six weeks after drug administra-
tion. Our patient’s symptoms started only 1.5 weeks after start-
ing sulfasalazine. Second, there was no evidence of peripheral 
eosinophilia or facial edema on admission (although she ex-
perienced facial edema later in her course). Last, there was no 
evidence of an elevated serum alanine aminotransferase (ALT) 
level. Despite the atypical time course, our patient’s rash start-
ed 1.5 weeks after a culprit drug (sulfasalazine) was initiated. 
Statistically speaking, sulfasalazine (and less likely ranitidine) 
was considered to be the cause of DRESS in this patient since 
sulfasalazine has been implicated in 10 cases according to the 
RegiSCAR’s Score and ranitidine was not included.7 Ranitidine 
is even labeled as a “miscellaneous cause” by Criado et al.8
In approximately 30% of cases, there is eosinophilia in DRESS 
syndrome but it can be delayed for one to two weeks.1,9 Liver 
abnormalities with elevated serum ALT are found in approxi-
mately 70% of patients with DRESS syndrome, although one 
series of 27 patients found it in more than 95% of them.10,11 The 
most common skin biopsy findings are a dense, perivascular 
lymphocytic infiltrate in the papillary dermis, with the presence 
of extravasated erythrocytes, eosinophils, and dermal edema.2 
Our patient’s skin biopsy revealed a perivascular lymphoid 
infiltrate with rare neutrophils and extravasated erythrocytes.
According to RegiSCAR diagnostic criteria,12 our patient met 
criteria for DRESS. The patient must: 1) have an acute rash, 2) 
have drug-related symptoms, 3) require hospitalization, and 
three of the following four signs: fever > 38C, enlarged lymph 
nodes involving > 2 sites, involvement of > 1 internal organ, 
and blood count abnormalities. Final scores: < 2: excluded; 2 – 3: 
possible; 4 – 5: probable; > 5: definite.13 The diagnosis of DRESS 
should be suspected with the presence of skin rash, liver in-
volvement, hyper-eosinophilia, and lymphadenopathy in the 
setting of fevers. The standard of care is to stop the suspected 
causative agent and initiate systemic corticosteroids. Systemic 
corticosteroids are the current mainstay of treatment. A recom-
mended starting dose is 1.0 – 1.5 mg/kg/day of prednisone or 
an equivalent drug and this dosage should be slowly tapered 
over 6 - 8 weeks to avoid a flare-up of symptoms.14 Further stud-
ies are needed to recommend specific treatment guidelines. 
CONCLUSION
Often in medicine, physicians are confronted with diag-
nostic dilemmas. Our case highlighted the importance of the 
history and physical examination in maintaining a broad dif-
ferential and making an accurate diagnosis. Internists must 
be aware of DRESS and its common culprit medications, as 
it is a potentially fatal diagnosis if left untreated. Prompt di-
agnosis is important to treat the underlying disease process.
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